Funder
Regeneron Pharmaceuticals, Inc.
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Madduri D, Hagiwara M, Parikh K, et al. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future Oncol. 2021;17:503–15.
2. American Cancer Society. Cancer facts & figures 2020. Available at https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. Accessed 6 June 2024.
3. Drugs.com. Find drugs & conditions. Available at https://www.drugs.com/. Accessed 6 June 2024.
4. Kaplan DA. Multiple myeloma: top 10 advances in the past 10 years. Target Ther Oncol. 2022;11:70.
5. Bobin A, Leleu X. Recent advances in the treatment of multiple myeloma: a brief review. Fac Rev. 2022;11:28.